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Ras genes are among the most commonly mutated genes in human cancer; yet
our understanding of their oncogenic activity at the molecular mechanistic level
is incomplete. To identify downstream events that mediate ras-induced cellular
transformation in vivo, we analyzed global microRNA expression in three different
models of Ras-induction and tumor formation in zebrafish. Six microRNAs were found
increased in Ras-induced melanoma, glioma and in an inducible model of ubiquitous
Ras expression. The upregulation of the microRNAs depended on the activation of
the ERK and AKT pathways and to a lesser extent, on mTOR signaling. Two Ras-
induced microRNAs (miR-146a and 193a) target Jmjd6, inducing downregulation
of its mRNA and protein levels at the onset of Ras expression during melanoma
development. However, at later stages of melanoma progression, jmjd6 levels were
found elevated. The dynamic of Jmjd6 levels during progression of melanoma in the
zebrafish model suggests that upregulation of the microRNAs targeting Jmjd6 may be
part of an anti-cancer response. Indeed, triple transgenic fish engineered to express a
microRNA-resistant Jmjd6 from the onset of melanoma have increased tumor burden,
higher infiltration of leukocytes and shorter melanoma-free survival. Increased JMJD6
expression is found in several human cancers, including melanoma, suggesting that the
up-regulation of Jmjd6 is a critical event in tumor progression.
The following link has been created to allow review of record GSE37015: http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?token=jjcrbiuicyyqgpc&acc=GSE37015.
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INTRODUCTION
Activating mutations in the RAS genes or in other members of the ras-signaling pathways
are very common in cancer1 and recent deep sequencing data of cancer genomes2 suggest
that these mutations are important primers of malignancies. Still, the initial molecular events
following activation of the pathways downstream of Ras are extremely difficult to study in vivo.
1http://www.sanger.ac.uk/genetics/CGP/cosmic/
2http://cancergenome.nih.gov/
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Transgenic models, where the expression of the oncogene leads to
cancer development in a reproducible manner provide a suitable
experimental system for addressing the complexity of cellular
transformation in live animals. The oncogenic versions of the
human RAS genes (KRAS, HRAS, and NRAS) have been the first
and most successful drivers of cancer in transgenic mice (Chin
et al., 1999a,b; Johnson et al., 2001; Malumbres and Barbacid,
2003). This ability of ras oncogenes to initiate and maintain
cancer has been related to global molecular and epigenetic
changes at early stages of transformation. Among the targets of
oncogenes, microRNAs are well-suited to sustain global changes
of cellular functions. Changes in several protein levels may be
regulated by a single or just a few microRNAs and a number of
microRNAs have been found deregulated in cancer (Harrandah
et al., 2018). Yet, very few studies have investigated their roles
at the onset of transformation as possible “global effectors” of
oncogenesis. In this study we have investigated the link between
Ras-induced transformation and microRNA expression, using
genetically tractable zebrafish models where the expression of a
constitutively active HRASG12V allele leads to the development
of different cancer types. We found that activated Ras signaling
promotes the rapid increase of six microRNAS. Interestingly, two
of these microRNAs target the same gene, Jmjd6, a jumonjiC
domain protein with at least two reported functions: histone
arginine demethylation (Chang et al., 2007) and mRNA splicing
regulation (Webby et al., 2009). Results reported here indicate
that Jmjd6 is a critical player in zebrafish melanoma development
and that at least two Ras-induced microRNAs antagonize Jmjd6
activation.
RESULTS
Dynamic Regulation of MicroRNAs by
RAS Activation
To identify miRNAs that are regulated by oncogenic Ras from
the earliest stages of transformation, we used a custom Agilent
microarray (see M&M). We profiled miRNA expression in
transgenic zebrafish overexpressing HRASG12V in melanocytes
(Santoriello et al., 2010), in brain cells (Mayrhofer et al., 2017) and
ubiquitously (Santoriello et al., 2009) (Figure 1A). Six miRNAs
(miR-21.1, miR- 21.2, miR-146a, miR-146b-1, miR-193a, miR-
193a-1) were up-regulated (log2FC > 1.2 and p-value < 0.01,
see Supplementary Table S1) in all three transgenic models at
3 day post-fertilization (dpf) and in 7 dpf melanoma, whereas no
commonly down-regulated miRNAs were found (Figure 1B and
Supplementary Table S1, highlighted rows).
This study, we focused on the melanoma model, and to clarify
the potential roles of the upregulated microRNAs in melanoma
progression, we analyzed microRNA expression levels at four
time points (3, 7, and 14 dpf and in adult tumors, Supplementary
Table S1) during melanoma progression. Next, we designed
Taqman probes for the active strand (−5p) of miR21, miR-146a
and miR-146b and for the active strand (−3p) of miR-193a and
validated the expression levels of the six upregulated miRNAs
by qPCR in the melanoma model (Figure 1C). The expression
of the six microRNA genes showed dynamic patterns: one was
upregulated up to 7 dpf (miR-146b-1-5p), while the others
were upregulated to different extents up to adult melanoma
(Figure 1D and Supplementary Table S1). To further validate the
dependence of these microRNAs on ras we used drugs that target
different pathways downstream of ras. Next, expression levels of
miR-21-5p (including both mir21-1 and miR21-2), miR-146a-5p,
miR-146b-1-5p, and miR-193a-3p (including also mir193a-1-3p)
were quantified through qPCR, after induction of ras expression
and in the presence of drugs. For simplicity, the microRNAs
under study are named miR-21, miR-146a, miR-146b, miR-193a
from now on.
The Increase of miR-21, miR-146a, and
miR-193a Is Ras-Dependent
To investigate whether miR-21, miR-146a, miR-146b, and miR-
193a are direct targets of ras, we analyzed their expression profiles
using an inducible model, Tg(hsp70l:EGFP-HRASV12)io3, called
HS-RAS, that expresses oncogenic ras upon heat shock. RNA
was extracted from 3 dpf HS-RAS embryos, 6 h after a 30 min
heat shock treatment at 37◦C, when robust ras activation occurs
(Santoriello et al., 2009). QPCR data show that miR-21 and
miR-146a are significantly upregulated in Ras overexpressing
larvae (Figure 2A), thus supporting the hypothesis that miR-
21 and miR-146a represents early-response targets, likely to
be directly induced by oncogenic Ras. MiR-193a and miR-
146b did not show significant upregulation in response to ras;
however, we performed the inhibitor experiments also on these
two microRNAs as they had shown to be upregulated in the
melanoma model (Figure 1C).
xs To identifying which signaling pathway(s) downstream of
Ras induces overexpression of these microRNAs, we blocked
specific pathways in HS-RAS larvae using small chemical
inhibitors of ERK, AKT and mTor phosphorylation (Figure 2B).
To check the efficacy of the inhibitors, we collected treated
larvae at 3 dpf and performed western blot analysis for known
targets of the three inhibitors. As shown in Figure 2C PD98059,
rapamycin and LY29004 were able to decrease ERK-P, AKT-
P and S6-P levels, respectively. Next we checked the levels of
microRNAs in inhibitor treated larvae using qPCR. As shown
in Figures 2D,E, induction of miR-21 and -146a expression
was greatly attenuated by all three inhibitors and most robustly
by the ERK inhibitor. MiR-146b levels were not affected by
the drug treatments (Figure 2F) and miR-193a levels were
reduced to statistically significant levels only when larvae were
treated with rapamycin (Figure 2G). These data suggest that
miR-21, miR-146a and to a less extent, miR-193a, are ras-
responsive genes and their activation is regulated mostly by
the MAPK/ERK and mTOR (for miR-193a) branches of ras
signaling.
Predicted Target of MicroRNAs 146a and
193a
As the function of miR-21 is widely studied in cancer (Frezzetti
et al., 2011), and miR-146b was found not to respond to
Ras signaling, in this study we focused on miR-146a and -
193a, to clarify whether they have a role in melanomagenesis.
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FIGURE 1 | miR-21, miR-146a/b, and miR-193a are upregulated by oncogenic RAS in transgenic cancer models. (A) Zebrafish models used in the study of
Ras-dependent microRNAs. Green fluorescence denotes the expression of the eGFP-fused oncogene. In Kita:Ras GFP labels transformed melanocytes and
notochord; in zic:Ras GFP marks ras-expressing brain cells; in HS-Ras, eGFP-Ras is expressed in whole embryos. For full description of transgenic lines, see text.
(B) Diagram depicting the overlap between the three sets of upregulated microRNAs. (C) Taqman QPCR analysis of miR-21, miR-146a/b, and miR-193a expression
levels in 3 dpf kita-RAS larvae compared to control (CT) larvae. The error bar represents the SEM of a triplicate experiment. (D) Heatmap representation of
microarray analysis of miR-21, miR-146a/b, and miR-193a expression at different stages of melanoma progression. Distinct precursor sequences and genomic loci
that express identical mature sequences are named on the form miR-21-1 and miR-21-2. Lettered suffixes denote closely related mature sequences. –5p and –3p
indicate the 5′ and 3′ arm respectively. ∗P ≤ 0.05 and ∗∗P ≤ 0.01.
A web-based target prediction algorithm [MicroCosmTargets,
now incorporated in www.tools4mirs.org (Lukasik et al., 2016)],
was used to identify potential targets of zebrafish miR-146a and
miR-193a. The tool is based on the genome assembly ZV93
and returned a few targets that were selected to contain seed
sequences for miR- 146a, miR-193a or both, this last category
included only jmjd6. We then used a web-based interaction-
prediction algorithm for RNA molecules, IntaRNA4 (Mann et al.,
2017) for the fast and accurate prediction of interactions between
miR-146a and/or 193a with jmjd6 mRNAs using the newest
genome assembly, GRCz115. This search confirmed the presence





Jmjd6 Is a Target of miR-193a and
miR-146a
Danio rerio jmjd6 has 1 transcript (Ensemble, ENSDAR
G00000102896). The 3′ UTR region of Jmjd6 contains miRNA
recognition elements (MREs) for miR-146a (Supplementary
Figure S1A), and MREs for miR-193a (Supplementary
Figure S1B). To determine whether Jmjd6 is a bona fide
target of miR-193a and miR-146a, we tested whether miR-
193a and miR-146a expression affects jmjd6 levels using an
in vivo GFP reporter assay. The entire jmjd6- 3′ UTR was
cloned downstream of green fluorescent protein (GFP) open
reading frame (Figure 3A). In vitro synthesized mRNA from
this construct was then injected into single-cell zebrafish
embryos with or without miR-193a or mir-146a duplexes
(Figure 3A), which mimic microRNA overexpression. The
injection of the microRNA duplexes resulted in increased levels
of microRNA (Supplementary Figure S2A) and caused mild
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FIGURE 2 | The increase of miR-21, miR-146a/b, and miR-193a is RAS-dependent. (A) Taqman QPCR analysis of miR-21, 146a, 146b, and 193a expression
following ras upregulation (6 h after heat-shock induction), ∗p < 0.05. (B) Diagram showing the ras pathway inhibitors used and their targets. (C) Western Blot
analysis of ERK-P, AKT-P, and S6-P ribosomal protein levels after the inhibitors treatment. (D–G) Taqman qPCR analysis in 3 dpf HS-RAS zebrafish treated with
PD98059, LY29004 and rapamycin. The error bars represent the SEM of a triplicate experiment; two tailed Student’s test was used for analysis. ∗p < 0.05.
or no phenotypes (Supplementary Figure S2B). The following
day, GFP expression levels were monitored by fluorescence
microscopy (Figure 3B) and by western blot analysis with an
antibody against GFP (Figures 3C,D). In both assays, GFP
levels were reduced in embryos injected with miR-193a or
miR-146a duplexes. Duplex injection of either miR-146a or
miR-193a also resulted in reduction of Jmjd6 protein levels
(Figures 3E,F).
To validate the direct interaction between miR-
146a and miR-193a with jmjd6 mRNA, we performed
RNA immunoprecipitation (RIP, Figure 3G). After
immunoprecipitation (IP) with Ago2 antibody, which selectively
enriched for RISC complex components (Ikeda et al., 2006),
jmjd6 transcripts were readily found in embryos injected with
miR-146a and miR-193a duplexes (Figure 3H) suggesting that
a physical interaction between jmjd6 transcripts and specific
microRNAs occurs in the RISC complex. These data confirmed
the interaction between miR-146a and miR-193a with jmjd6
mRNA.
As we found that jmjd6 is a target of miR-146a and -
193a, we investigated whether the level of jmjd6 was lower
in Ras expressing larvae compared to controls. As shown
in Supplementary Figures S3A,B heat-shock induced Ras
overexpression results in down-regulation of jmjd6 RNA level
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FIGURE 3 | Jmjd6 is a target of miR-146a and miR-193a. (A) Effects of increasing microRNA levels on a Jmjd6-GFP sensor expression. Diagram of the construct
used as sensor. (B) Representative images of 24 hpf zebrafish embryos injected with the Jmjd6-3′ UTR GFP sensor and the microRNA duplexes as indicated.
Arrows illustrate the direction of the changes in expression. (C) Western blot analysis of GFP expression and (D) quantification of the changes in Jmjd6-3′ UTR GFP
sensor levels upon microRNA overexpression. (E) Reduction of Jmjd6 protein levels following miR-146a, and miR-193a duplex injection in 3 dpf embryos shown by
Western Blot analysis. (F) Quantification of the Western Blot shown in (E). (G) RIP (RNA immuno precipitation) diagram and (H) analysis of jmjd6 transcripts in the
RISC complex following duplex injections in 3 dpf embryos.
(Supplementary Figure S3A, column 2) and jmjd6 protein
levels (Supplementary Figure S3B, lane 2). To test if jmjd6
down-regulation was due to increased expression of miR-
146a and/or miR-193a, we reduced microRNA expression by
injecting morpholinos (MO) specific to miR-146a or miR-193a
and measured jmjd6 mRNA and protein levels in morpholino
injected HS-Ras embryos. All morpholinos were able to reduce
expression levels of their targets (data not shown) and to
increase the levels of jmjd6 transcripts, repressed by ras, to
levels similar to controls (Supplementary Figure S3A, columns
3–4) and protein levels (Supplementary Figure S3B, lanes 3–
4), suggesting that ras-induced miRs are responsible for the
downregulation of jmjd6 levels observed in response to ras
expression.
Jmjd6 in Melanoma
In our model of melanoma progression, where ras is
overexpressed in melanocytes, jmjd6 levels are reduced compared
to control larvae at 3 and 7 dpf (Figure 4A). However, at 14 dpf,
there is no significant difference in jmjd6 levels between kita:Ras
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FIGURE 4 | JMJD6 is up-regulated in zebrafish and human melanoma. (A) Jmjd6 mRNA levels in 3, 7, 14 days kita-RAS zebrafish and (B) in adult melanoma
developing in two different genetic backgrounds, as shown. The error bars represent the SEM of triplicate experiments; two tailed Student’s test was used for
analysis. ∗p < 0.01. (C) Analysis of JMJD6 expression in a variety of cancers from the cBioPortal database; every spot represents a case. (D) Expression of JMJD6
(brown nuclear staining) in control skin and in a malignant melanoma from the Protein Atlas website (https://www.proteinatlas.org/ENSG00000070495-JMJD6).
and controls. We then analyzed the levels of jmjd6 expression
in full-blown melanoma in two different genotypes: wild type
(p53+/+) and p53−/−. In the latter background, melanomas
developed earlier and were highly invasive from the earliest
stages (Santoriello et al., 2010). QPCR analysis of jmjd6 levels
in six wild type and in three p53−/− cases showed significantly
higher levels of expression of jmjd6 in melanoma, especially in
tumors developing in a p53−/− genetic background (Figure 4B).
Given the unexpected increase of jmjd6 expression in
melanoma, and its correlation with a more aggressive phenotype
(Liu et al., 2017), to understand the clinical relevance of
our findings, we queried online databases to investigate
the expression levels of miR-146a, miR-193a and JMJD6 in
melanoma samples from human patients. Data reported here on
human melanoma are derived from publicly available resources,
as stated in the following text and in the figure’s legend. While
no changes in miR-193a expression were reported in melanoma,
a couple of studies (GSE18509 and GSE31568, see dbDEMC
at www.picb.ac.cn/dbDEMC/index.html) reported an increase
of miR-146a in melanoma (not shown). Next, we analyzed the
expression levels of JMJD6 in different types of cancers, including
melanoma, using the website cBioPortal for Cancer Genomics6
(Cerami et al., 2012). As shown in Figure 4C, we found that
JMJD6 is upregulated in different cancers, with melanoma being
one of the cancer having higher levels of JMJD6 expression and
high genomic alteration frequency (with amplification in almost
3% of cases, Supplementary Figure S4A). Looking carefully into
the skin cutaneous melanoma TCGA dataset we found that the
levels of JMJD6 are upregulated in 16% of human cutaneous
melanoma (72 out of 469 patients, Supplementary Figure S4B).
6http://www.cbioportal.org/
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Moreover, JMJD6 expression levels are higher in the samples with
HRAS and BRAF mutations compared to samples with wild type
HRAS and BRAF (Supplementary Figures S4C,D), suggesting
that JMJD6 is upregulated by RAS signaling in these melanomas.
Patients with alteration of JMJD6 (mutations, amplifications,
deep deletions, or multiple alterations) have a worse overall
survival and disease/progression-free survival compared with
patients with wild type JMJD6 (Supplementary Figures S4E,F),
suggesting a key role of JMJD6 in disease progression.
Next, we investigated the levels of JMJD6 protein in human
melanoma using the website Protein Atlas7 (Uhlen et al., 2017).
The website reported medium (in three patients) or high (in
nine patients) nuclear JMJD6 immunostaining in malignant
melanoma. An example of a high JMJD6 immunostaining in
melanoma is shown in comparison to control skin (where JMJD6
is not expressed) (Figure 4D) (Uhlen et al., 2017). These data
suggest that the microRNA-mediated downregulation of jmjd6
in the zebrafish progressive melanoma model is a transient
event and at later stages of melanoma development or in
more aggressive melanomas in fish and in human, Jmjd6 is
overexpressed.
Expression of miR-Resistant Jmjd6
Promotes Ras-Induced Melanoma
Given the dynamic changes in Jmjd6 expression in the Ras-
induced melanoma model in zebrafish, and the overall increase in
expression in human melanoma, we wanted to clarify the role of
Jmjd6 in melanoma with a gain of function approach. Therefore,
we produced a transgenic line that expresses miR (146a and
193a) -resistant jmjd6 in melanocytes. This was achieved by
replacing the 3′ UTR of jmjd6 in the transgenic construct
with an artificial sequence (SV40 polyA, Figure 5A). With this
construct, we generated a tg(UAS:eGFP-jmjd6) transgenic line
using standard Tol2 transposase methods (Kawakami, 2004),
and crossed it to kita:Gal4 fish. The double transgenic fish,
designated as kita:Jmjd6, have no phenotype; however eGFP-
Jmjd6 expression was confirmed by kita driven GFP nuclear
localization in melanocytes and notochord cells (Figures 5B–D).
To study the effects of combined expression of oncogenic
ras and Jmjd6 in melanoma we generated triple transgenic
fish, Et(kita:Gal4TA, UAS:mCherry)hmz1;Tg(UAS:eGFP-
HRASV12)io006; Tg(UAS:eGFP-JMJD6)ka202 (designated as
kita/Ras/Jmjd6, Figure 5E) and observe the fish for the
development of melanoma at regular intervals, from 7 days
to 1 month. As shown in the disease-free survival curve, 60%
of double transgenic kita-ras fish show melanoma at 1 month
(Figure 5F). However, triple transgenic fish kita/Ras/Jmjd6
developed melanoma at an earlier stage (Figures 5E,F) and by
1 month of age, penetrance of melanoma was 95% (Figure 5F).
The tumors appeared in multiple locations in the same fish
(Figure 5E) and were more invasive, as judged by the body
surface showing melanoma lesions and by histological analysis
(Figures 5G,H).
We also noticed that Kita/Ras/Jmjd6 melanomas have
massive infiltration of leukocytes (L-plastin+ cells), resembling
7https://www.proteinatlas.org/
macrophages and neutrophils for their shape, much higher than
in to Kita/Ras melanomas (Figures 5I–L).
DISCUSSION
In this study we used a progressive model of melanoma
in zebrafish to study the changes of microRNA expression
at the onset of RAS-induced transformation and throughout
progression of the disease. We found six microRNAs, which are
upregulated as an early response to oncogenic RAS expression
in three different models. As two of these microRNAs target
Jmjd6 we investigated the significance of these interactions
for melanoma progression. To our surprise we discovered
that the target of these increased microRNAs, Jmjd6, is
overexpressed in aggressive zebrafish melanoma. This suggested
that overexpression of Jmjd6 promotes melanoma progression
and that the increase of the microRNAs that downregulate Jmjd6
at the onset of Ras expression is part of a defensive response
against the pro-oncogenic activity of Jmjd6. We validated this
hypothesis by generating triple transgenic zebrafish that express
micro-RNA resistant Jmjd6. Melanoma develop faster in the
kita/ras/jmjd6 fish, supporting a pro-oncogenic role of Jmjd6.
Further work is needed to clarify how Jmjd6 favors melanoma
development.
Jmjd6 is a JumanjiC-domain containing protein, which has
been endorsed for different functions. It was initially identified as
a phosphatidylserine receptor (PSR) on the surface of phagocytes
(Fadok et al., 2000). Ablation of Jmjd6 in mice, and morpholino
downregulation of Jmjd6/PSR in zebrafish (Hong et al., 2004)
causes abnormal development and leads to neonatal lethality
in mouse (Böse et al., 2004; Kunisaki et al., 2004). However,
many lines of evidence argue against a function of Jmjd6 as a
PSR, primarily its nuclear localization (Cui et al., 2004; Tibrewal
et al., 2007), and a number of newly reported nuclear activities.
Subsequently, Jmjd6 was shown to function as an arginine
demethylase, which removes repressive symmetric methylation
marks from histone 2 (H2R3me2s) and histone 4 (H4R3me2s)
arginines (Chang et al., 2007), but other groups have been unable
to confirm the arginine demethylation activity of JMJD6 (Hahn
et al., 2010). Webby et al. (2009) reported that JMJD6 acts as a
lysyl-5-hydroxylase of the splice factor subunit U2A65. Silencing
of JMJD6 expression in endothelial cells resulted in abnormal
splicing of the VEGF receptor 1 (Boeckel et al., 2011). Meanwhile,
a structural study suggested that methyl groups on single-
stranded RNAs (ssRNAs) might be substrates of JMJD6 (Hong
et al., 2010). More recently, a proteomic approach identified
JMJD6 as one of a few binding partners of the bromodomain
and extraterminal (BET) domain protein Brd4 (Rahman et al.,
2011), which regulates gene expression through interaction with
the cdk9 subunit of the positive transcription and elongation
factor, pTEFb complex (Jang et al., 2005). Further studies lead
to the identification of JMJD6 as the partner of BRD4 in
binding distal enhancers known as anti-pause enhancers, which
regulate release from transcriptional pausing in a large subset of
transcriptional units which depend on long-range interactions
(Liu et al., 2013). Here, the demethylase activity of JMJD6 on
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FIGURE 5 | Expression of miR-resistant Jmjd6 promotes Ras-induced melanoma. (A) Schematic representation of the construct used to generate a transgenic line
expressing microRNA-resistant Jmjd6 under the UAS promoter. Cmlc2-GFP is the cardiac myosin light chain promoter driving GFP expression in the heart as marker
of transgenesis. (B–D) Examples of GFP staining in crosses between the UAS lines and the kita:Gal4 line (as indicated). Expression is visible in the notochord (Distel
et al., 2009) and in melanocytes in all kita crosses (B–D), and in the heart for the UAS:Jmjd6 line, C,D) GFP is localized to the nucleus for Jmjd6-GFP or the plasma
membrane for eGFP-HRASV12. (E) Double or triple transgenic larvae and juveniles at the indicated stages of development. (F) Disease- free survival curve of the
double or triple transgenic fish. N = 100 for kita; 321 for kita:Ras; 211 for kita:Ras:Jmjd6. Long-rank test: p-value < 0,0001. (G,H) H&E staining of representative
melanoma sections from transgenic fish as indicated. (I–L) Immunostaining for L-plastin (red florescence) and GFP (only in I–K, indicating HRASV12, green
fluorescence) in representative melanoma sections from transgenic fish as indicated. Calibration bar: 100 µm for (B,D), 50 µm for (I–L).
the snRNA, 7SK, results in the disassembly of the transcriptional
repressive complex HEXIM1-7SK, releasing pTEFb from pausing
(Liu et al., 2013). It would be interesting to study whether anti-
pause enhancers, which are the substrates of the JMJD6-Brd4
interaction, are associated with pro-oncogenic gene expression
in melanoma. Given the robust correlation between Jmjd6
overexpression and aggressive melanoma in different models and
in human samples, it would be important to clarify if the pro-
oncogenic function of JMJD6 depends on this transcriptional
activity. More recently, Liu et al. (2017) have shown that the
JMJD6 promotes melanomagenesis through the regulation of the
alternative splicing of PAK1, a key MAPK signaling component.
In recent years, also RNA binding abilities of Jmjd6 are emerging,
perhaps its many functions, linked to arginine methylation of
RNA binding proteins in transcription initiation complexes,
spliceosome and ribosomes may be mediated by its RNA-binding
abilities. Indeed Heim et al. (2014), showed that treatment with
RNAse disrupt Jmjd6 nuclear localization.
In our study we found that two microRNAs induced by Ras
(miR-146a and miR-193a) behave as tumor suppressors. MiR-
146a and b are well-studied for their roles in immune responses.
Induced by inflammation and infection through NF-kB signaling
(Bhaumik et al., 2008), miR-146a, and to a lesser extent miR-146b,
function in a negative feedback loop to downregulate several pro-
inflammatory effectors. Indeed miR-146a has been implicated
in attenuating pro-inflammatory responses (Saba et al., 2014),
which could contribute in cancer to the elimination of early
transformed cells by the immune system, and in reducing the
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metastatic potential of breast cancer cells (Bhaumik et al., 2008).
Increase in expression of miR-146a was reported in unclassified
melanoma samples (Philippidou et al., 2010), and found to
suppress brain metastasis from melanoma in experimental
models (Hwang et al., 2013). These findings support a tumor
suppressor role for miR-146a in melanoma. Our study provides
evidence that miR-146a is induced by the same MAPK/AKT
pathway that sustains melanoma growth at the earliest stages of
transformation, when it could exert an anti-melanoma function
by repressing Jmjd6 and perhaps also pro-tumoral inflammation.
The tumor suppressive activity of miR-193a has been related to
its ability to inhibit cell proliferation and to promote apoptosis
of cancer cells (Nakano et al., 2013; Mamoori et al., 2018). MiR-
193a undergoes epigenetic silencing in acute myeloid leukemia by
the AML1/ETO fusion protein (Li et al., 2013), where miR-193
was found to repress several pro-leukemogenic factors, including
KIT. Moreover miR193a has been found to participate in a
regulatory loop that controls p53 family member levels (Ory et al.,
2011) thus further reinforcing the hypothesis that miR193a is
a tumor suppressor. The finding that both microRNAs target
Jmjd6 and that this regulation is conserved in zebrafish and
human melanoma suggests that lowering JMJD6 levels in cancer
is another function of the tumor suppressors miR-146a and
miR-193a.
The mechanisms through which Jmjd6 promote melanoma
progression is still unknown. Different approaches, including
transcriptome, epigenome and spliceosome analysis, can help
to gain insights into the pro-oncogenic activity of JMJD6. In
these studies, the transgenic lines kita:Jmjd6 and kita/Ras/Jmjd6
will provide a source of GFP tagged Jmjd6 proteins expressed
specifically in melanocytes. We were puzzled by the massive
presence of L-plastin positive cells (leukocytes, possibly including
neutrophils and macrophages) within the kita/Ras/Jmjd6
melanomas, compared to kita/Ras melanomas. Neutrophils and
eosinophil infiltrations in melanoma predict unfavorable disease
outcome (Ding et al., 2018) whereas accumulation of dendritic
cells and T-lymphocytes is positively correlated with survival.
Therefore, the increase of L-plastin positive neutrophils and
macrophages is an index of the aggressiveness of these tumors.
It is intriguing that one of the microRNAs targeting Jmjd6 in
this progressive model of melanoma is miR-146a, a well-known
regulator of inflammatory responses. It would be interesting
to investigate whether miR-146a levels differ in melanoma
developing in kita/Ras (where they are increased according to
RNA-Seq data) versus those developing in kita/Ras/Jmjd6.
In summary, this study has shown that several microRNAs
are induced by RAS signaling in melanoma initiating cells
at the onset of transformation. Induced miR-146a and -
193a target Jmjd6, which is temporarily downregulated.
At later stages of melanoma development, and in human
malignant melanoma with unfavorable prognosis, Jmjd6 is
overexpressed, and in a zebrafish model where melanocytes
express both Ras and Jmjd6, melanomas are more aggressive.
Therefore, Jmjd6 has pro-oncogenic activities and the initial
downregulation mediated by microRNAs may be part of an




Zebrafish were maintained and staged as described (Kimmel
et al., 1995).
In addition to wild type AB fish, we used the following lines:
- Et(kita:Gal4TA, UAS:mCherry)hmz1; Tg(UAS:eGFP-HRASV
12)io006 a double transgenic line in which oncogenic ras
expression is regulated by the kita promoter and that
develop melanoma (Santoriello et al., 2010), also crossed to
ZDF1 (p53m214k/+)(Berghmans et al., 2005).
- Tg(hsp70l:EGFP-HRAS_G12V)io3 an heat-inducible
oncogene expressing line (Santoriello et al., 2009).
- Et(zic4:Gal4TA4, UAS:mCherry)hzm5;Tg(UAS:eGFP-HR
ASV12)io006 a double transgenic line in which oncogenic
ras expression is regulated by the zic4 promoter and that
develop glioma (Mayrhofer et al., 2017).
- Et(kita:Gal4TA, UAS:mCherry)hmz1; Tg(UAS:eGFP-Jmj
d6)ka202; and Et(kita:Gal4TA, UAS:mCherry)hmz1; Tg(UAS:
eGFP-HRASV12)io006; Tg(UAS:eGFP-Jmjd6)ka202xs double
and triple transgenic lines in which the expression of a
microRNA resistant Jmjd6 is regulated by Gal4 expressed
under the kita promoter alone (double) or together
with HRASV12 (triple), generated in the course of this
study. This study was carried out in accordance with the
recommendations of the OPBA of the University of Trento
on Animal Welfare. Experimental procedures on zebrafish
were performed in accordance with the European law on
Animal Protection and Authorization No. 75/2017-PR
from the Italian Ministry of Health.
miRNA Array
Custom-designed 8 × 15k microarray slides were ordered from
Agilent Technologies. The 15k custom design was obtained
from Edwin Cuppen and Eugene Berezikov (Hubrecht Institute,
Utrecht, Netherlands) and has been submitted into the Gene
Expression Omnibus (GEO) database (GPL 15403). The 15k
design contained a duplicate of 7604 probes of 60-oligonucleotide
length. The probes consisted of 2 × 22 nucleotide sequences
antisense to mature miRNAs separated by a spacer of 8
nucleotides (CGATCTTT) and with a second spacer with the
same sequence at the end. From 7604 probes 546 were designed
for left (5′) and right (3′) arms of the hairpins of zebrafish
miRNAs that are known in miRBase, while the remainder 7058
probes corresponded to predicted hairpin structures in the
zebrafish genome that might include additional miRNAs but were
not considered in this study. Total RNA, including microRNA,
were extracted from 3-7-14 dpf wt or UAS-RAS larvae (driven by
kita:Gal4, zic:Gal4, or hsp:Gal4), and from adult melanoma or wt
fin tissue using miRNeasy Mini Kit R©(Qiagen). Three biological
replicates were obtained for each condition. For dual color
hybridization of the Agilent chips miRNA samples from RAS
transgenics were labeled with Hy3 and samples from control
fish were labeled with Hy5 with miRCURYTM LNA microRNA,
Hy3TM/Hy5TM Power Labeling kit (Exiqon) using 1 microgram
of total RNA according to the manufacturer’s instructions.
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The dual color hybridization of the microarray chips was
performed according to Agilent protocol GE2_105_Jan098 for
two-color microarray-based gene expression analysis except that
hybridization and washing was performed at 37◦C. The arrays
were scanned with DNA Microarray Scanner G2565CA from
Agilent Technologies. The arrays were scanned twice with 10%
PMT and 100% PMT laser power. Microarray data was processed
from raw data image files with Feature Extraction Software 9.5.3.1
(Agilent Technologies). The XDR function was used to extend
the dynamic range. Processed data were subsequently imported
into Rosetta Resolver 7.1 (Rosetta Biosoftware, Seattle, WA,
United States) and subjected to default ratio error modeling.
The raw data have been submitted to GEO under accession
number GSE 37015. Values above 1.2 log2 Fold Changes and
p-values < 0.01 in all three models were used as selection criteria.
QPCR for MicroRNAs
To confirm microarray data, total RNA, including miRNA,
were purified from 3 dpf embryos using miRNeasy Mini
Kit R©(Qiagen). Mature miRNA were reverse transcribed using
specific primers mix for each miR to produce different cDNA
for TaqMan R©MicroRNA assay (30 ng of total mRNA for each
reaction) (Applied Biosystems). Taqman probes were designed
for the active strand (−5p) of miR-21, miR-146a, and miR-146b
and for the active (−3p) strand of miR-193a. Real-time PCR
reactions based on TaqMan reagent chemistry were performed in
duplicate on ABI PRISM R©7900HT Fast Real-Time PCR System
(Applied Biosystems). The level of miRNA expression was
measured using CT (cycle threshold). For normalization, miR-
133, which was unaffected by RAS overexpression, was taken
as reference. Fold change was generated using the equation
2−CT. The list of oligos used and their sequences is provided in
Supplementary Table S2.
Inhibitor Treatment
Three dpf HS-RAS and AB embryos were incubated in 2ml
E3 medium in a 12 well plate in the presence of the following
inhibitors: 1 µg/ml PD98059 (Calbiochem), 15 µM LY294002
(Cell Signaling) and 1 µM Rapamycin (Tocris). After 2 h,
embryos were heat-shocked at 39◦C for 30 min. After 6 h 50 RAS-
GFP+ or GFP- embryos were collected in Trizol or sample buffer
(2% SDS, 10% glycerol, 60 mM Tris pH 6.8) for miRNA or protein
extraction respectively.
Western Blot and Antisera
Ten 3 dpf embryos were homogenized in 200 µl sample buffer
(2% SDS, 10% glycerol, 60 mM Tris pH 6.8). 30 µg of total extract
were resolved by SDS-PAGE, transferred to nitrocellulose and
tested with the following antibodies: phospho-p44/42 (1:1000,
Cell Signaling), p44/42 (1:1000, Cell Signaling), Phospho-AKT
(1:1000, Cell Signaling), AKT (1:1000, Cell Signaling), Phospho-
S6 (1:1000, Cell Signaling), S6 (Cell Signaling 1:1000), jmjd6
(Abcam, 1:1000), GFP (1:1000, Torrey Pines, United States), actin
(1:5000, MP Biomedical).
8www.Agilent.com
Manual Inspection of 3′ UTR of
Candidate MicroRNA Targets
An initial analysis performed with MicroCosm (now
incorporated in tools4mirs at https://tools4mirs.org/) which
used a previous version of the zebrafish genome identified
a few genes as potential targets of both miR146a and 193a.
Manual inspection of the 3′ UTR regions of these genes using
the GRCz11 release at Ensembl5 confirmed that only jmjd6 3′
UTR region contained sequences that match the seed regions
of both microRNAs. We then used a web-based interaction-
prediction algorithm for RNA molecules, IntaRNA4 (Mann et al.,
2017) for the fast and accurate prediction of the interactions
between miR-146a and/or 193a with jmjd6 mRNAs (Ensemble,
ENSDARG000001028965). We followed the web-site instructions
and used jmjd6 and miR-146a-5p and -193a-3p sequences as
input. The following parameters were used: minimum number
of base pairs in seed: 7; temperature for energy computation:
37◦C; energy parameter set (Vienna package), Turner Model
2004 (Lorenz et al., 2011); energy interaction levels <−8.
Morpholino, Duplexes, and Plasmids
Morpholinos, including a standard control morpholino, were
obtained from Gene Tools (United States), titrated to non-toxic
concentrations and injected in a final volume of 2 nl per 1-
cell embryo. A list of all morpholinos, their sequences and the
concentration used is provided in Supplementary Table S3.
Synthetic miR- duplexes controls and 146a were designed and
ordered from SIGMA (United States). Synthetic miR- duplexes
for miR-193a were purchased from Ambion. Duplexes were
dissolved in RNAse free water and diluted using annealing buffer
(30 mM HEPES-KOH pH 7.4, 10 mM KCl, 2 mM MgCl2,
50 mM NH4Ac) to a final concentration of 10 µM for miR-
146a 5 µM for miR-193a. The solution was incubated for 1 min
at 90◦C, cooled down slowly to room temperature and injected
in a final volume of 2 nl per 1-cell embryo. A list of all
duplexes, their sequences and the concentration used is provided
in Supplementary Table S4.
For Jmjd6 reporter construct, the whole Jmjd6 (Ensemble,
ENSDARG00000102896) 3′ UTRs was PCR amplified from cDNA
using specific primers (Supplementary Table S2). The PCR
product was subcloned into the pCS2:eGFP vector downstream
of the GFP open reading frame and confirmed by sequencing.
Generation of a Jmjd6 Transgenic Line
To express a microRNA resistant Jmjd6 in melanocytes, the full
coding region excluding the stop codon of Jmjd6 (Ensemble,
ENSDARG00000102896) was PCR amplified and cloned into
pEntry5-no stop (Invitrogen) and then recombined using gateway
technology with a pEnt5-4nrUAS (generated by cloning four
non-repetitive UAS elements into pENT5′ from Invitrogen),
a p3E-EGFPpA (Tol2Kit clone n.366) + pDestTol2CG2
(Tol2Kit clone n. 395) using gateway (Kwan and North, 2017).
Clone numbers and sequences can be found at:
http://chien.neuro.utah.edu/tol2kitwiki/index.php/Main_Page.
Final recombined clones were checked by sequencing.
4nrUAS:eGFP-Jmjd6 plasmid was injected in 1-cell embryos
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of the Et(kita:Gal4TA, UAS:mCherry)hmz1 line to generate a
transgenic line using standard Tol2 mediated transgenesis
(Kawakami, 2004; Pase and Lieschke, 2009).
Zebrafish Embryo Injections
Zebrafish embryos at the stage of 1–2 cells were injected with
morpholinos against miRs or Jmjd6 diluted in double distilled,
sterile H2O. The morpholino oligonucleotides were injected at
a concentration of 5 ng/nl, in a volume of 2 nl/embryo. miR
duplexes mimicking mature microRNA were injected following a
described protocol (Pase and Lieschke, 2009), at a concentration
of 10 µM for miR-146a and miR-146b and 5 µM for miR193a in
a volume of 2 nl/embryo.
Sensor injections: mRNA encoding for eGFP carrying Jmjd6
3′ UTR was in vitro synthesized and injected in 1–2 cell
zebrafish embryos at 100 pg/embryo, alone or in combination
with duplexes or morpholinos.
Imaging
Photographs of whole larvae were acquired with a Nikon
S100 stereomicroscope equipped with epifluorescence and
multiple filters. We used a Leica SP5 confocal for analysis
of melanocytes expressing Ras-eGFP, Jmjd6-GFP, and L-plastin
immunoreactivity.
AGO2 – RIP
One hundred 3 dpf embryos injected or not with miR duplex
were homogenized in ice-cold buffer A containing 50 mM Tris-
HCl pH 7.5, 5 mM EDTA, 5 mM EGTA, complete proteinase
inhibitor (Roche) and 1 U/µl RNAse inhibitor SUPERnase-IN
(Ambion). Unbroken cells were removed at 100 g for 5 min at
4◦C. NP40 was added at 0.5% (wt/vol) and samples incubated at
4◦C for 15 min with rotation and centrifuged at 10000 × g for
15 min. SN was the transferred to a new tube and the protein
were measured by BCA. 2 mg of protein were diluted with
buffer A and incubated overnight at 4◦C with 50 µl Dynabeads
(Invitrogen) bound with 2 µg Ago2 antibody (Abcam) or IgG
(negative control). The next morning beads were washed four
times with 1 ml of washing buffer containing 50 mM Tris-HCl
pH 7.4, 150 mM NaCl, 1 mM MgCl2 and 0.05% NP40. Beads
were then resuspended in 1ml of washing buffer and 200 µl of
beads were pelleted and resuspended in 50 ul sample buffer to test
Ago2 by western blot (Abcam 1:1000). The remaining 800 ul were
resuspend with 500 µl of trizol and RNA was extracted by RNeasy
micro Kit (Qiagen). All the RNA was retro-transcribed using Vilo
(Invitrogen) and 1 µl of cDNA was used for PCR using specific
primers for jmjd6 or the housekeeping gene, gapdh.
Analysis of Data From cBioportal and
Protein Atlas
Analysis of JMJD6 expression, correlation with HRAS or BRAF
mutations, survival and disease/progression-free survival
in patients was done using the dataset Skin Cutaneus
Melanoma TCGA dataset in cBioportal6. The survival and
disease/progression-free survival were done taking into account
the following JMJD6 alterations: mutations, amplifications, deep
deletions or multiple alterations.
We report here examples of JMJD6 protein localization in
control skin (ID: 23969) and in a malignant melanoma (ID:
213610) from the Protein Atlas website.
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FIGURE S1 | Output of IntaRNA website, showing interaction of microRNAs 146a
(A) and 193a (B) with the 3′ UTR of jmjd6. An energy of −8 Kcal/mol or less is
indicative of a stable interaction.
FIGURE S2 | Injections of duplexes microRNAs cause increase of the
corresponding microRNAs and mild developmental defects. (A) QPCR analysis of
the expression levels of the microRNAs indicated. (B) All the other injected
embryos developed without visible abnormalities.
FIGURE S3 | Jmjd6 is down-regulated upon Ras expression. Jmjd6 mRNA (A)
and protein levels (B) are downregulated by Ras overexpression (2nd lane) and
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FIGURE S4 | cBioPortal data of JMJD6. (A) Alteration frequency of JMJD6 in
different type of cancers. (B) JMJD6 expression in melanoma patients; each bar
represents a patient. Red bars: patients with upregulated JMJD6. Blue bars:
patients with downregulated JMJD6. JMJD6 expression in HRAS (C) and BRAF
(D) mutated melanoma. Overall survival (E) and disease/progression-free survival
(F) in patients with (red curve) or without (blue curve) JMJD6 alterations.
TABLE S1 | miRNA array results table. Column A: probe ID; column B: sequence
of the probe; column C: Gene ID; column D: Gene symbol; Columns E–P: fold
change and relative p-value of the samples as indicated. Fold change and p-value
are calculated by comparing the miRNAs expression in kita-Ras larvae at 3, 7, and
14 dpf, HS-Ras, and zic at 3 dpf and adult melanoma with the respective control
(AB for all the larvae and skin from adult AB wild type fish for the adult melanoma).
MicroRNAs selected for further studies (see text for criteria used) and their
expression values (log2FoldChanges and pValues) are highlighted.
TABLE S2 | Oligo sequences. Sequences of the oligos used for qPCR, RIP assay,
jmjd6 3′-UTR cloning and Gateway cloning of Jmjd6.
TABLE S3 | Morpholino sequences. Sequences of the morpholinos used in the
study.
TABLE S4 | microRNA duplexes. Sequences of the miR control (miR-C) and
miR-146a_l injected in the embryos. The sequence of miR-193a was not provided
by the supplier (Ambion).
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